| The vaccine made by the Cambridge, Mass., biotechnology company is poised to be authorized after a detailed review by the Food and Drug Administration confirmed that the two-shot regimen was 94 percent effective in a clinical trial and carried no serious safety concerns. The FDA document, released exactly a week after a similar one for the Pfizer-BioNTech vaccine, positions Moderna's vaccine to follow the same historic track. | 
No comments:
Post a Comment